REAL-WORLD ECONOMIC OUTCOMES OF FIRST-LINE (1L) IBRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)

被引：0
|
作者：
Challagulla, S. [1 ]
Lee, P. [2 ]
Kistler, K. [3 ]
Douyon, L. [3 ]
Lai, D. [2 ]
Iyengar, R. [2 ]
机构：
[1] Pharmacyclics LLC, Fremont, CA USA
[2] Pharmacyclics LLC, Sunnyvale, CA USA
[3] Xcenda, Palm Harbor, FL USA
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN101
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 50 条
  • [1] Real-World Clinical Outcomes of First-Line (1L) Ibrutinib Dose Reduction Versus Acalabrutinib Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Shadman, Mazyar
    Karve, Sudeep
    Abbazio, Christopher
    Majd, Zahra
    Bacchus, Shaffee
    Saifan, Chadi
    Gogna, Priyanka
    Manceur, Ameur M.
    Lafeuille, Marie-Helene
    Emond, Bruno
    Srivastava, Bhavini P.
    Stephens, Deborah M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S352 - S352
  • [2] Real-world clinical outcomes in patients receiving either ibrutinib or chemoimmunotherapy (CIT) as first-line (1L) treatment for chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL): A retrospective analysis.
    Wu, Linda
    Ran, Tao
    He, Jinghua
    Panjabi, Sumeet
    Lu, Xiaoxiao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Real-world outcomes following adverse events and dose reduction of first-line ibrutinib in Medicare beneficiaries with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Shadman, Mazyar
    Srivastava, Bhavini P.
    Salkar, Monika
    Saifan, Chadi
    Agatep, Barnabie C.
    Jones, Barton
    Ryan, Olga
    Bacchus, Shaffee
    Stephens, Deborah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Retrospective Analysis of Real-World Outcomes of Chronic/ Small Lymphocytic Leukemia (CLL/SLL) Patients Treated With First-Line Ibrutinib Versus Chemoimmunotherapy (CIT)
    Ran, Tao
    He, Jinghua
    Wu, Linda
    Panjabi, Sumeet
    Lu, Xiaoxiao
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S275 - S276
  • [5] Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL)
    Krackeler, Margaret
    Chee, Bryant
    Orchanian, Arthur K.
    Law, Lisa Y.
    Lopez, Alfredo R.
    Buchanan, Susan
    Maglinte, Gregory A.
    Liu, Raymond
    Zhu, Zheng
    Sakoda, Lori C.
    Tavakoli, Jahan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC)
    Khelifi, Rania S.
    Huang, Steven J. T.
    Savage, Kerry J.
    Villa, Diego
    Scott, David W.
    Ramadan, Khaled
    Connors, Joseph M.
    Sehn, Laurie H.
    Toze, Cynthia L.
    Gerrie, Alina S.
    BLOOD, 2020, 136
  • [7] Real-World Outcomes with First-Line Ibrutinib (Ibr) Versus Chemoimmunotherapy (CIT) in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Final Analysis Results from the InformCLL Registry
    Ghosh, Nilanjan
    Sharman, Jeff P.
    Barrientos, Jacqueline C.
    Brander, Danielle
    Gutierrez, Meghan
    Wu, Linda
    Qureshi, Zaina P.
    Upasani, Sandhya
    Naganuma, Maoko
    Mato, Anthony R.
    BLOOD, 2022, 140 : 7047 - 7049
  • [8] Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL).
    Hainsworth, JD
    Litchy, S
    Burris, HA
    Greco, FA
    BLOOD, 2001, 98 (11) : 363A - 363A
  • [9] Real-World Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First-Line (1L) Therapy in the United States (US)
    Mato, Anthony R.
    Ravelo, Arliene
    MyTo, Tu
    Schuldt, Robert
    Biondo, Juliana M. L.
    BLOOD, 2021, 138
  • [10] Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Lu, Xiaoxiao
    Emond, Bruno
    Qureshi, Zaina
    He, Jinghua
    Qian, Yi
    Huang, Qing
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Jacobs, Ryan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S280 - S281
12345